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Statement of clinical relevance 
Analysis of body fluids by peptidomics has demonstrated a significant value in the context of 
biomarker discovery. However, the origin of specific peptides generally remains unclear. 
With this study, we analyzed and sequenced human plasma and urinary peptides using a 
combination of techniques (CE-MS, and CE- and LC-MS/MS). As a first step towards 
predicting the origins of native peptides, we also investigated any overlaps in the data from 
the two sources. The results indicated surprisingly little overlap between plasma and urine 
peptides, also supported after investigating additional, previously published, urine and plasma 
peptidomics datasets. The most plausible hypothesis based on these data is that most plasma 
peptides may be reabsorbed in the renal tubules. Collagens appear to be an exception 
displaying a positive correlation and/or a much higher relative abundance in urine versus 
plasma suggesting the existence of a mechanism for their selective excretion. 
Abstract 
Purpose: Urine is considered to be produced predominantly as a result of plasma filtration in 
the kidney. However, the origin of the native peptides present in urine has never been 
investigated in detail. Therefore, we aimed to obtain a first insight into the origin of urinary 
peptides based on a side-by-side comprehensive analysis of the plasma and urine peptidome. 
Methods: Twenty-two matched urine and plasma samples were analyzed for their peptidome 
using capillary electrophoresis coupled to mass spectrometry (CE-MS; for relative 
quantification) and CE- or LC coupled to tandem mass spectrometry (CE- or LC- MS/MS; 
for peptide identification). The overlap and association of abundance of the different peptides 
present in these two body fluids were evaluated. 
Results: We were able to identify 561 plasma and 1461 urinary endogenous peptides. Only 
90 peptides were detectable in both urine and plasma. No significant correlation was found 
when comparing the abundance of these common peptides, with the exception of collagen 
fragments. This observation was also supported when comparing published peptidome data 
from both plasma and urine.   
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Conclusions and clinical relevance: Most of the plasma peptides are not detectable in urine, 
possibly due to tubular reabsorption. The majority of urinary peptides may in fact originate in 
the kidney. The notable exception is collagen fragments, which indicates potential selective 
exclusion of these peptides from tubular reabsorption. Experimental verification of this 
hypothesis is warranted. 
1. Introduction 
Proteomics via mass spectrometry (MS) has become a widely used technique for detecting 
proteins and characterizing their abundances in a range of biological samples.
[1,2]
 Multiple 
studies have been published focusing on the urinary
[3-6]
 and plasma proteomes,
[7,8]
 as these 
two fluids are considered easily accessible, valuable sources of information. After sampling, 
the urine proteome content is relatively stable (in part due to the fact that urine has normally 
been “stored” in the bladder for several hours, hence any proteolytic processes are 
completed), as opposed to blood where proteases are activated after collection.
[8-10]
  
Plasma and urine contain thousands of proteins that are expected to be linked to a large 
extent. The kidney filters ~ 1500 L of blood daily in the glomeruli, generating ~170 L 
primary urine (assuming a GFR of 120 ml/min). Most of its components are further 
reabsorbed in the tubules, while the excreted urine volume represents about 1% of the 
original ~170 L volume.
[11]
 Consequently, urinary protein composition is the result of a 
combination of plasma proteins filtered into the urine by glomerular filtration minus tubular 
reabsorption, and proteins originating from the kidney and urinary tract (e.g. secreted from 
renal tubular epithelial cells, and/or shedding of whole cells along the urinary tract, including 
shedding of apical membranes of renal tubular epithelial cell, and exosome secretion).
[11-13]
 
Extracting information from online databases, Jia et al.
[12]
 compared plasma and urine 
proteomes, characterizing their potential overlap. Based on this comparison, they were able to 
study the potential association of detected proteins with kidney function. The authors 
proposed that this methodology, based on proteomic techniques, might be relevant for 
understanding organ (kidney) functions and body homeostasis. In 2014, Farrah et al.
[14]
 
compared kidney, urine and plasma proteome based on relative protein abundances, 
determining potential kidney-specific proteins, de novo urine proteins, and proteins filtered 
from plasma. The resulting data confirmed that the proteome of urine and plasma are 
associated.
[12]
 It has been suggested that under physiological conditions 70% of the urinary 
proteins originate from the kidney and the urinary tract, and 30% are plasma proteins.
[13]
 In 
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kidney disease, the glomerular filtration barrier is altered, affecting directly the above-
mentioned distribution.  
To date, the majority of studies comparing plasma and urine focused on proteome 
analysis.
[12,14]
 In the context of peptide profiling, plasma provides a more stable peptidome 
readout than serum.
[15]
 This is mostly due to the fact that proteolytic activity involved in 
coagulation is higher in serum than in plasma.
[15,16]
 Recently, Parker et al.
[17]
 described over 
5500 endogenous plasma peptides, providing a comprehensive description of the plasma 
native peptidome. On the other hand, urinary native peptides have been extensively 
investigated, especially in the context of kidney disease,
[18,19]
 clearly showing that peptides 
are a rich source of information. In 2008, Coon et al.
[20]
 described the first peptidomic 
database on naturally occurring urinary peptides, named Human Urinary Proteome database. 
This database is regularly updated, currently storing datasets from over 50 000 urine samples 
(healthy controls and patients with different diseases), encompassing endogenous peptide 
signals and respective sequence information.
[21,22]
 Multiple studies have shown that such 
endogenous urinary peptides combined in classifiers represent powerful tools in the diagnosis 
and clinical assessment of several diseases such as kidney diseases,
[23-25]
 different 
cancers,
[26,27]
 and cardiovascular diseases.
[28-30]
 However, less is known about the origin of 
these peptides. At first sight, it seems reasonable to assume that the origin of peptides follows 
the same rule as the proteins: about 30% of urinary peptides may originate from plasma by 
the process of filtration, while the major fraction originates from the kidney and the urinary 
tract. However, since peptides are expected to pass the filtration barrier in the glomerulus and 
in general should all be collected in urine, we hypothesized that a higher fraction (in 
comparison to proteins) of plasma-derived peptides are present in urine. Unfortunately, no 
evidence or data (not even indirectly) are readily available to support this (or any other) 
hypothesis. 
As a first step towards investigating the origin of endogenous urinary peptides, we analyzed 
twenty-two matched urine and plasma samples by CE-MS profiling and tandem-MS. Based 
on these data, we established a map of the plasma and urinary peptidome dataspaces in these 
individuals, and determined their overlap, and abundance correlation. These data were further 
placed in the context of existing literature and available plasma and urine peptidomic 
datasets. Collectively, the results support that most of the plasma peptides are not detectable 
in urine, possibly due to tubular reabsorption, and lead to the additional hypothesis of 
potential selective exclusion of specific peptides (mainly collagens) from this process.  
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2. Material and methods 
2.1. Urine and plasma collection 
Plasma and urine samples derived from twenty-two subjects were analyzed to obtain CE-MS 
peptide profiles and CE-MS/MS and LC-MS/MS peptide sequences. Table 1 reports the 
characteristics of the subjects.  
Urine samples were collected, stored at -20°C and shipped frozen for subsequent peptidome 
analysis. All blood samples were taken via vein puncture, collected in anticoagulant-treated 
tubes (9 heparin and 13 EDTA), immediately cooled to 4°C and centrifuged at 1200×g for 10 
min.
[31]
 The plasma was isolated and stored at -80°C. All plasma and urine samples were 
collected at the same time point. 
The study was conducted fulfilling all the laws on the protection of individuals being 
involved in medical research and in accordance with the principles of the Declaration of 
Helsinki. All plasma and urine data were obtained anonymized. The local ethics committee 
from Hannover Medical School (Hannover, Germany) approved the approach, employing 
anonymized samples and proteomics data (Ethical ID: 3596-2017).  
2.2. Plasma and urine sample preparation  
For urine samples 0.7 mL and for plasma samples 0.3 mL plus 0.4 mL of H2O (as described 
in,
[31]
 without delipidation) was used and diluted with 0.7 mL of 8 M urea, 10 mM NH4OH, 
and 0.02% SDS. Ultrafiltration was performed to remove high molecular weight proteins, 
using Centrisart ultracentrifugation filters (20 kDa MW cut-off; Sartorius) at 2,600×g. To 
remove urea, electrolytes, salts, and thereby to decrease matrix effects, a volume of 1.1 mL of 
the filtrate was applied onto a PD-10 desalting column (Amersham Bioscience, Uppsala, 
Sweden) equilibrated in 0.01% NH4OH in high-performance liquid chromatography 
(HPLC)-grade H2O (Roth, Germany). After rinsing the column with 1.9 ml of 0.01% 
NH4OH in H2O, 2 mL of HPLC-grade H2O was applied and the resulting eluate was 
collected. The eluate was lyophilized, stored at 4°C and resuspended in HPLC-grade H2O 
shortly before analysis, as previously described.
[32]
 The generation of this protocol and basic 
features (reproducibility, peptide recovery, etc.) are reported in detail in Theodorescu et 
al..
[33]
 In addition, performance characteristics are comprehensively described in Mischak et 
al..
[32]
 
2.3. CE-MS analysis and data processing  
CE-MS analysis was performed as previously described
[32]
 in the same fashion for urine and 
plasma. A P/ACE MDQ capillary electrophoresis system (Beckman Coulter, Fullerton, CA) 
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was coupled with a Micro-TOF MS (Bruker Daltronic, Bremen, Germany). A solution of 
20% acetonitrile (Sigma-Aldrich, Taufkirchen, Germany) in HPLC-grade water (Roth, 
Karlsruhe, Germany) supplemented with 0.94% formic acid (Sigma-Aldrich) was used as 
running buffer. For CE-MS analysis, the electrospray ionization interface from Agilent 
Technologies (Palo Alto, CA) was set to a potential of -4.0 to -4.5 kV. Spectra were recorded 
over an m/z range of 350-3000 and accumulated every 3 s. Monoisotopic mass signals were 
determined for z≤6 with resolution in the range of 10 000 and a limit of detection of ~1 fmol 
as previously described.
[32]
 
Mass spectral ion peaks representing identical molecules at different charge states were 
deconvoluted into single masses using MosaiquesVisu software, which employs a 
probabilistic clustering algorithm and uses isotopic distribution (for z≤6) as well as 
conjugated masses for charge-state determination of peptides/proteins.
[34]
 Only signals with 
z>1 observed in a minimum of 3 consecutive spectra with a signal-to-noise ratio of at least 4 
were considered. All detected peptides were clustered, matched and deposited in a Microsoft 
Structured Query Language (SQL) database.
[20]
 The result is a peak list, characterizing each 
protein and peptide by its molecular mass [Da] and normalized CE migration time [min]. 
Migration time and ion signal intensity (amplitude) of the urinary peptides were normalized 
similarly to previous studies using internal peptides.
[35]
 For normalization of CE-time of the 
plasma peptides, we used 470 peptides. 20 internal standard peptides present in almost all 
plasma samples were used for normalization of signal intensity. 
Analysis by CE-MS was employed for the relative quantification of the peptides in each 
sample, whereas MS/MS analysis (coupled to either CE- or LC to maximize coverage) was 
used for peptide sequencing (described below). Only peptides identified in the cohort 
described in the present study were reported and further combined into a peptide list. Missing 
values (in general the result of abundance being below the detection limit) in the individual 
samples were considered as “zero”. 
2.4. MS/MS analysis  
CE-MS/MS analysis was performed as described.
[36]
 Concisely, the CE was connected to an 
Orbitrap Velos FTMS (Thermo Finnigan, Bremen, Germany). Sample was ionized using a 
modified Proxeon nano spray source fitted with a non-grounded Agilent ESI sprayer 
operating in positive ion mode. Ionization voltage was 3.4 kV and the capillary temperature 
was 275°C. The mass spectrometer was operated in MS/MS mode scanning from 350 to 1500 
amu. The top five multiply charged ions were selected from each scan for MS/MS analysis 
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using HCD at 40% collision energy. The resolution of ions in MS1 was 60.000 and 7.500 for 
MS2.  
For LC-MS/MS analysis, aliquots of 5 µL were analyzed on a Dionex Ultimate 3000 RSLS 
nano flow system (Dionex, Camberly, UK) at a flowrate of 5 µL/min. The trap and nano flow 
column were maintained at 35°C. After loading (5 µL) onto a Dionex 0.1 × 20 mm 5 µm C18 
nano trap column, elution was performed on an Acclaim PepMap C18 nano column 75 µm × 
15 cm, 2 µm 100 °A at a flowrate of 0.3 µL/min. Typically, samples were eluted with a 
gradient of solvent A: 97.9% H2O, 0.1% formic acid, 2% acetonitrile versus solvent B: 80% 
acetonitrile, 19.9% H2O, 0.1% formic acid starting at 1% B for 5 min rising to 20% B after 90 
min and finally to 40%B after 120 min.  
Thereafter, the column was washed and reequilibrated prior to the next injection. The eluant 
was ionized using a Proxeon nano spray ESI source operating in positive ion mode into an 
Orbitrap Velos FTMS (Thermo Finnigan, Bremen, Germany). Ionization voltage was 2.6 kV 
and the capillary temperature was 250°C. The mass spectrometer was operated in HCD 
MS/MS mode.  Using HCD, the top 20 multiply charged ions were selected from each scan 
for MS/MS analysis and only charge state one was rejected for MS/MS.
[36]
 The detection 
limit for the LC- or CE-MS/MS analysis using the Orbitrap Velos mass spectrometer, with 60 
000 resolution for MS1 and with 7500 resolution for MS2, was in the range of 0.05 – 0.2 
fmol. 
In order to obtain sequence information, CE- and LC-MS/MS were used as complementary 
approaches.
[36]
 CE-MS/MS has the advantage of direct matching (mass and CE-time) to the 
peptides quantified by CE-MS. On the other hand, LC-MS/MS exhibits higher sensitivity due 
to the increased loading capacity of the LC-column, consequently a better coverage of 
sequence information. However, the retention time in LC does not directly correspond to the 
CE migration time, which represents a disadvantage of LC-MS/MS in this approach.   
The obtained sequences were matched to the previously quantified peptides assessed by CE-
MS (section 2.3). 
2.5. Sequence data analysis 
Data files were searched against the UniProt human non-redundant database using Proteome 
Discoverer 1.2 (Thermo) and the SEQUEST search engine. Relevant settings were: no fixed 
modifications, oxidation of methionine and proline as variable modifications. The minimum 
precursor mass was set to 790 Da, maximum precursor mass to 6000 Da with a minimum 
peak count of 10. The high confidence peptides were defined by cross-correlation (Xcorr) 
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≥1.9 and rank=1. Precursor mass tolerance was 5 ppm and fragment mass tolerance was 0.05 
Da. 
False discovery rate settings cannot guarantee that the correct sequence is assigned to a 
fragmentation spectrum generated in an MS/MS experiment.
[37]
 However, a property of CE is 
that the migration time is dependent on the net positive charge of the peptide. At pH 2 (pH of 
the running buffer) this (charge) is a function of the number of basic amino acids present.
[38]
 
The peptide sequences obtained from the tandem MS analysis were matched to the CE-MS 
peaks by matching the molecular mass and migration time (in the case of CE-MS/MS) or 
molecular mass and theoretical migration time based on the number of basic amino acids (in 
the case of LC-MS/MS). In addition and to further allow matching, the absence of cysteine 
and absence of hydroxylated proline in non-collagen peptides were required. If a sequence 
passed all of these criteria it was then assigned to the corresponding CE-MS peak.
[38]
 
2.6. Peptides data processing 
The mean peptide abundance was calculated by multiplying the mean of the amplitudes of 
each individual peptide with its frequency (as defined by the occurrence of each peptide 
present in a given cohort).  
Prior to the statistical analysis, the relative abundance of peptides in the respective body fluid 
(urine or plasma) was calculated following the equation:   
Relative abundance of specific peptide (%) = Mean peptide abundance*100 / Total 
abundance of all overlapping peptides  
2.7. Statistical analysis 
Pearson correlation coefficient r and regression analysis were performed to evaluate the 
association of the abundances of respective peptides identified in plasma and urine.  P-values 
less than 0.05 were considered statistically significant. MedCalc software (version 12.7.5.0; 
MedCalc Software, Mariakerke, Belgium) was used to perform these analyses and to generate 
the corresponding graphs. 
3. Results  
3.1. Plasma peptidome profile 
The plasma data comprised of 9 heparin and 13 EDTA samples. In previous experiments, we 
have compared both plasma types and found no significant differences between them. 
Analysis of the 22 aforementioned plasma samples by CE-MS resulted in the detection of 
approximately 700 peptide signals per sample, which could be combined in a total of 1952 
unique endogenous peptides. Sequence information was obtained for 561 out of the 1952 
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(28%) plasma peptides using a combination of CE- and LC-MS/MS analysis (supplementary 
table 1, „plasma‟). When considering the abundance of the peptides in plasma, these 561 
sequenced peptides covered approximately 24% of the total detected peptide-signal.  
The intensity across the sequenced plasma peptides corresponded by 55.9% to complement 
fragments (C3 and C4-A), 25.1% fibrinogen fragments (alpha and beta chain), 5.5% 
apolipoprotein fragments, 4.1% different collagen fragments, and 9.4% fragments from 
various proteins (e.g. serum albumin, thymosin beta-4, alpha-2-antiplasmin, alpha-1-
antitrypsin and inter-alpha-trypsin inhibitor heavy chain H1 and H4) (Table 2A). Moreover, 
when sorted based on abundance, the 10 most abundant plasma peptide fragments were seven 
complement C3, two-fibrinogen alpha chain, and one-apolipoprotein A-IV peptide 
(supplementary table 1, „plasma‟).  
3.2. Urine peptidome profile 
CE-MS analysis of the 22 individual urine samples led to the detection of approximately 
1800 peptide signals per sample, which could be combined in a list of 3955 unique urinary 
endogenous peptides. Sequence information was obtained for 1461 peptides (37%) 
(supplementary table 1, „urine‟). The abundance of the aforementioned sequenced peptides 
covered approximately 52% of the total detected urine peptide-signal.  
Of the total abundance of identified (sequenced) peptides in urine, collagen fragments 
comprised 79.5%, uromodulin 8.2%, fibrinogen 6%, and 6.3% were fragments originated 
from other proteins such as polymeric-immunoglobulin receptor, CD99 antigen, 
sodium/potassium-transporting ATPase subunit gamma, and membrane associated 
progesterone receptor component 1 (Table 2B). Along these lines and based on signal 
intensity (abundance), the 10 most abundant urinary peptides comprised eight collagen 
fragments (type I, II and III), one uromodulin and one fibrinogen fragment (supplementary 
table 1, „urine‟).   
3.3. Comparison of plasma and urine peptidome profiles 
3.3.1. Overlap of urinary and plasma peptides 
Subsequently, we investigated the overlap of urinary and plasma peptides. This analysis 
resulted in the identification of 90 common peptide sequences (Figure 1), including collagen 
and fibrinogen fragments and fragments derived from other proteins such as serum albumin, 
osteopontin, apolipoprotein (A-1 and L1) and alpha-2-HS-glycoprotein. Corresponding 
sequence information and relative abundance of these peptides in plasma and urine are 
reported in supplementary table 2. As shown (supplementary tables 1-2), the majority of 
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sequenced peptides were exclusively present in plasma or in urine. Among the peptides 
apparently present only in plasma were peptides derived from plasminogen activator inhibitor 
1, H/ACA ribonucleoprotein complex subunit, guanine nucleotide exchange factor VAV3, 
complement C4-A, apolipoprotein E, alpha-2-antiplasmin, and 5-oxoprolinase. Peptides 
seemingly restricted to urine, therefore likely originating from kidney or urinary tract were 
peptides derived from polymeric-immunoglobulin receptor, CD99 antigen, 
sodium/potassium-transporting ATPase subunit gamma, and membrane associated 
progesterone receptor component 1. 
3.3.2. Correlation of overlapping peptides in urine and plasma 
Next, we studied the correlation of the relative abundance (%) of identical peptides in urine 
and plasma. No significant correlation (r = 0.05; p-value = 0.632) could be observed when 
investigating all 90 overlapping peptides (Figure 2A). However, when investigating only the 
collagen fragments (n=71, representing 78% of the overlapping peptides), a significant 
correlation of abundance in urine and plasma could be detected (r = 0.32; p-value = 0.007) 
(Figure 2B). Moreover, investigating only collagen alpha-1 (I) chain fragments (n=50, 
representing 56% of the overlapping peptides) a correlation of apparently even higher 
significance was found (r = 0.44; p-value = 0.002) (Figure 2C).  
3.4. Placing of findings in the existent literature  
To investigate if our results are also reflected in published urine and plasma peptidomics 
datasets, two well-described sequenced peptide lists were further analyzed 
[17,21,22]
. 
Specifically, for urinary peptides, sequence information was extracted from the Human 
Urinary Proteome database.
[21,22]
 We were able to retrieve 3366 urinary peptides, where high-
confidence sequence information was assigned.
[21,22] In the case of plasma, sequence 
information of 5548 native plasma peptides, previously identified by Parker et al., was 
extracted.
[17]
 Evaluation of the overlap of the two sets resulted in the identification of 124 
common peptides in plasma and urine (Figure 3A). In agreement with the findings above, no 
significant correlation (p=0.09) of the relative abundance of these peptides could be observed 
(Figure 3B). 
4. Discussion  
The urinary and plasma peptide profiles of 22 individuals were evaluated with the aim of 
generating a map of the urinary and plasma peptidome, and creating a hypothesis on the 
origin of the former. The data generated expands the current knowledge in the field, which 
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may also be helpful for further clinical proteomic studies, where peptide-biomarkers may be 
targeted based on their potential origin. 
In the current study, we identified and sequenced 1461 urinary peptides. Surprisingly, most of 
these peptides were exclusively found in urine such as uromodulin, CD99 antigen, and 
polymeric-immunoglobulin receptor, suggesting that these are kidney or urinary tract derived. 
Given that urine represents a concentrate plasma filtrate, we cannot rule out the possibility 
that some of these peptides may in fact be present in plasma, yet at very low abundance 
(below our detection limits). Interestingly, many of these aforementioned peptides have been 
found to be associated with kidney diseases.
[23,39,40]
 In addition, collagen fragments were the 
most abundant peptides in urine, as also previously reported.
[20,23]
 
In contrast, the plasma peptidome comprised mostly of peptides originating from proteins 
associated with the circulatory system.
[10]
 In this study, we were able to sequence 561 plasma 
peptides. Peptide fragments belonging to apolipoprotein E and complement C4-A proteins 
were uniquely identified in plasma. Furthermore, peptides derived from complement and 
fibrinogen represented the most abundant plasma peptides. These findings are in line with 
previous observations.
[17,41]
 In addition, when comparing the peptide relative abundances in 
our plasma dataset with that of the plasma peptidome described by Parker et al.,
[17]
 a 
significant correlation was observed (data not shown).  
The overlap between plasma and urine peptides (based on peptide sequence) was surprisingly 
small, considering that plasma peptides are expected to be filtered by the kidney and 
consequently, are expected to be typically present in urine. Only 90 overlapping (identical) 
peptides derived from various proteins such as collagen, serum albumin, osteopontin, alpha-
1-antitrypsin, and apolipoprotein fragments could be identified, which in the vast majority of 
cases, did not correlate with abundance. Such low overlap is also observed when 
investigating previously published urine and plasma peptidomics datasets.
[17,21,22]
 This lack of 
overlap may in part be associated with the low abundance of some of these peptides in 
plasma, not allowing their detection. In contrast, the primary urine is concentrated ~100-fold 
in the tubulus (from about ~150-180 L to 1.5 L daily output);
[11]
 hence, the concentration of 
peptides in urine also is expected to be increased, facilitating their identification. The most 
plausible hypothesis for this finding relates to the tubular reabsorption process: under 
physiological conditions, proteins and peptides in the primary urine are thought to be 
removed/reabsorbed in the proximal tubule
[11,42]
 by two receptors, megalin and cubilin.
[43]
 
This process does not appear to be selective and should apply to all proteins and peptides 
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equally. As a result, general reduction of the amount of plasma proteins and peptides in urine 
should be observed. Differential proteolytic activity may also contribute to the observed 
differences. Plasma and urinary peptides might be a result of different proteolytic processes. 
Hence, a peptide derived from the circulation may be cleaved by a kidney-specific protease 
(e.g. dipeptidyl peptidase-4 (DPP4)),
[44]
 which could ultimately result in further peptide 
degradation, revealing a different sequence even if the peptide is from the same protein 
origin.  
Interestingly and as an exception, when investigating collagen-derived peptides, or more 
specifically, type I collagen-derived peptides, a significant correlation of the relative 
abundance in urine and plasma could be observed. This finding indicates that collagen 
derived peptides may be selectively excluded from tubular reabsorption via a yet unknown 
mechanism (Figure 4). This is a hypothesis meriting further investigation, including studies 
addressing the existence of biological functions for some of these peptides.  
CE and LC coupled to MS present certain advantages and disadvantages, which were 
previously described in detail.
[36,45]
 Briefly, for CE a constant flow and voltage settings are 
used. This approach displays high robustness and fast analysis time, as well as high peak 
resolution. LC has a higher sensitivity, due to the possibility of loading higher amounts of 
sample. In addition, separation time (and resolution) can be extended by applying a shallow 
gradient, which allows better coverage (increased number of peptide identifications). 
The study has several limitations, but none of these appear to have a severe impact on the 
main conclusion: that the plasma peptidome bears very little similarity to the urine 
peptidome, and that our findings indicate selective exclusion of specific peptides from tubular 
reabsorption. A certain limitation of the study may be the consistently lower number of 
peptides identified in plasma in comparison to urine. However, this is likely due to the 
aforementioned differences in abundance. The expected increase in relative abundance of 
peptides in urine may be attenuated by tubular reabsorption, but apparently not for all 
peptides equally. An additional limitation of the study may be the relatively low number of 
subjects included. For further refinement of the peptide content especially of plasma, 
additional studies in an expanded sample cohort and/or under different sample collection and 
preparation conditions may be required. However, the observed consistency of our results 
with earlier reports,
[17,41]
 including the most abundant peptides in plasma, supports the 
validity of the findings presented here. Further work has to be conducted towards the 
identification (at the amino acid level) of the yet unidentified peptides, putatively associated 
www.clinical.proteomics-journal.com Page 13 Proteomics - Clinical Applications 
 
 
This article is protected by copyright. All rights reserved. 
13 
 
with the presence of post-translational modifications.
[46]
 However, we could identify close to 
500 peptides in this study, indicating a quite valid representation of the peptides typically 
expected in plasma.  
To our knowledge, this study represents the first approach to compare plasma and urinary 
peptidome based on the same methodology and samples from same subjects, with novel and 
quite unexpected findings. Comparing plasma and urine peptidome may allow a better 
understanding of the origin of the urinary peptides. Furthermore, this study revealed various 
interesting findings opening up new research avenues for the future: the presence of specific 
peptides (collagen fragments), significantly correlated with and/or at much higher relative 
abundance in urine versus plasma may be suggestive of the existence of an underlying reason 
and mechanism for their selective excretion - a hypothesis meriting further experimental 
investigation. Future studies will need to reveal the physiology behind this observation, and 
utilize this knowledge to increase the specificity of urinary peptide markers for a given 
disease.  
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Table 1. Characteristics of the study population 
 
Characteristics 
Number of subjects 22 
Age (years) 46.59±15.42 
Gender (F/M) 10/12 
 
 
Table 2. Distribution of plasma and urinary peptides, indicating the percentage related to the 
total number of identified peptides and the coverage (abundance) across the sequenced 
peptides 
A. Plasma peptides 
 
Number of 
identified peptides 
% of total number 
of identified 
peptides 
% coverage of total 
detected peptide-
signal (abundance) 
Complement (C3 and C4-A) 49 8.7% 55.9% 
Fibrinogens (alpha and beta chains) 182 32.4% 25.1% 
Apolipoproteins 82 14.6% 5.5% 
Collagens 126 22.5% 4.1% 
Others 122 21.8% 9.4% 
B. Urinary peptides 
 
Number of 
identified peptides 
% of total number 
of identified 
peptides 
% coverage of total 
detected peptide-
signal (abundance) 
Collagens 966 66.1% 79.5% 
Uromodulin 29 2% 8.2% 
Fibrinogens (alpha and beta chains) 26 1.8% 6% 
Others 440 30.1% 6.3% 
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Figure legends 
Figure 1. Comparison between urine and plasma based on the identical sequenced peptides  
1371 peptides exclusively identified in urine (e.g. polymeric-immunoglobulin receptor, CD99 antigen, 
sodium/potassium-transporting ATPase subunit gamma, and membrane associated progesterone receptor 
component 1); 90 overlapping peptides (collagen fragments, fibrinogen fragments and fragments derived from 
other proteins (e. g. serum albumin, osteopontin, apolipoprotein and alpha-2-HS-glycoprotein));  471 peptides 
only identified in plasma (e.g. plasminogen activator inhibitor 1, H/ACA ribonucleoprotein complex subunit, 
guanine nucleotide exchange factor VAV3, complement C4-A, apolipoprotein E, alpha-2-antiplasmin, and 5-
oxoprolinase) 
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Figure 2. Correlation of the urine and plasma peptides found among the overlap based on 
their relative abundance in both sources. Correlation A. of all peptides, B. of all collagen 
peptides, and C. of only peptides from collagen alpha-1(I) chain 
 
*A1AT: Alpha-1-antitrypsin; ALBU: Serum albumin; APOA1: Apolipoprotein A-I; APOL1: Apolipoprotein L-
I, CO1A1: Collagen alpha-1(I) chain; CO1A2: Collagen alpha-2(I) chain; CO3A1: Collagen alpha-1(III) chain; 
COEA1: Collagen alpha-1(XIV) chain; FETUA: Alpha-2-HS-glycoprotein; FIBA: Fibrinogen alpha chain; 
FIBB: Fibrinogen beta chain; OSTP: Osteopontin  
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Figure 3. A. Comparison of Human Urinary Proteome database
[21,22]
 and plasma peptidome 
listed in
[17]
 based on the identical sequenced peptides. B. Correlation of the overlapping 
peptides based on their relative abundance 
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Figure 4. Representation of the expected and our main findings, related to filtration and 
reabsorption processes, and urinary excretion  
 
 
Supplementary tables 
Supplementary table 1: Spreadsheet “Plasma” - Plasma peptides identified by CE- and LC-
MS/MS; Spreadsheet “Urine” - Urine peptides identified by CE- and LC-MS/MS  
Supplementary table 2: Peptides commonly identified in plasma and urine 
 
 
